Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In VFC To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in VFC between October 30, 2023 and May 20, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212- 983-9330Â (Ext. 1310). [You may also click here for additional information] NEW ...

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its growth and the impact of its CEO's health on the company's performance [3][4]. Company Summary - The class period for the lawsuit is from February 26, 2025, to August 8, 2025 [3]. - Allegations include that C3 AI's management provided overly positive statements while concealing material adverse facts about the company's growth potential and the CEO's health issues [3]. - On August 8, 2025, C3 AI announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing this to "the reorganization with new leadership" and the CEO's health [3]. - Following this announcement, C3 AI's stock price dropped from $22.13 per share to $16.47 per share, a decline of approximately 25.58% in just one day [3]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by October 21, 2025 [4]. - Registration allows shareholders to receive updates on the case and does not involve any cost or obligation [4]. Legal Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - The company, 卡倍亿, received an administrative regulatory measure decision from the Ningbo Securities Regulatory Bureau due to non-compliance with regulations regarding shareholder equity changes [1][2]. Group 1: Regulatory Actions - 卡倍亿 was ordered to correct its actions and engage in regulatory discussions following a violation of the "Management Measures for the Acquisition of Listed Companies" [2]. - The company must submit a written rectification report within ten working days of receiving the decision [2]. - The chairman and general manager, 林光耀, along with the board secretary and deputy general manager, 秦慈, are required to attend regulatory discussions [2]. Group 2: Shareholder Changes - On May 22, 2025, 卡倍亿's controlling shareholder, 宁波新协实业集团有限公司, increased its shareholding from 76,881,000 shares to 107,633,400 shares, raising its ownership percentage from 56.97% to 57.11% [1]. - The company failed to announce this change in shareholding as required when the percentage change reached an integer multiple of 1% [1]. Group 3: Previous Regulatory Issues - This is not the first time 卡倍亿 has faced regulatory scrutiny; the company received two warning letters within a month in the previous year regarding its executives [2]. - In April 2024, two executives received warning letters for engaging in short-term trading of company bonds, violating regulations [3]. - In May 2024, the deputy general manager, 秦慈, received a warning for purchasing company stock within 30 days prior to the annual report announcement, which also constituted a regulatory violation [3]. Group 4: Company Background - 卡倍亿 was listed on the Shenzhen Stock Exchange on August 24, 2020, with an initial public offering of 13.81 million shares at a price of 18.79 yuan per share [4]. - The total amount raised from the IPO was approximately 259.49 million yuan, with a net amount of about 215.88 million yuan after deducting issuance costs [4][5]. - The company has conducted multiple rounds of fundraising through convertible bonds, raising a total of approximately 1.067 billion yuan across three fundraising events [6][7].

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims is from April 29, 2025, to June 23, 2025 [2]. - The complaint claims that Hims engaged in deceptive promotion and selling of knockoff versions of Wegovy, risking patient safety [2]. - There is a substantial risk that the collaboration with Novo Nordisk could be terminated due to these practices [2]. - The positive statements made by the defendants regarding the company's business and operations were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased HIMS shares during the class period are encouraged to register for potential lead plaintiff appointment [1][3]. - The deadline for shareholders to register is August 25, 2025, and there is no cost or obligation to participate [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

NEW YORK, June 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citiz ...